Artal Group S.A. Regenxbio Inc. Transaction History

Artal Group S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$12.17 - $24.61 $3.04 Million - $6.15 Million	250,000 New	250,000 $5.27 Million
Q4 2020 Feb 11, 2021	SELL	$26.52 - $49.35 $5.9 Million - $11 Million	-222,300 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$27.01 - $40.26 $316,017 - $471,042	-11,700 Reduced 5.0%	222,300 $6.12 Million
Q2 2020 Aug 14, 2020	SELL	$27.75 - $43.44 $444,000 - $695,040	-16,000 Reduced 6.4%	234,000 $8.62 Million
Q1 2020 May 14, 2020	BUY	$21.5 - $54.2 $2.26 Million - $5.69 Million	105,000 Added 72.41%	250,000 $8.1 Million
Q2 2019 Aug 09, 2019	SELL	$42.0 - $59.29 $1.05 Million - $1.48 Million	-25,000 Reduced 14.71%	145,000 $7.45 Million
Q4 2018 Feb 11, 2019	BUY	$39.11 - $75.15 $782,200 - $1.5 Million	20,000 Added 13.33%	170,000 $7.13 Million
Q2 2018 Aug 10, 2018	SELL	$27.2 - $74.35 $2.72 Million - $7.43 Million	-100,000 Reduced 40.0%	150,000 $10.8 Million
Q4 2017 Feb 09, 2018	BUY	$26.0 - $34.6 $2.34 Million - $3.11 Million	90,000 Added 56.25%	250,000 $8.31 Million
Q3 2017 Nov 08, 2017	BUY	$18.0 - $32.95 $2.88 Million - $5.27 Million	160,000	160,000 $5.27 Million

196

43M

104K

478K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $340M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.